The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

From changing your eating windows to adding more fibre to your diet, there are simple tweaks you can make to how and what you ...

My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with medication, and he also has a history of recurrent prostate cancer. My mother ...

Josh Gad is sharing some candid updates about his life in a new interview. During his appearance on the " Armchair Expert " ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV special focuses on the drugs.

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...